US OptionsDetailed Quotes
BLUE240816C3000
- 0.18
- 0.000.00%
15min DelayClose Aug 16 15:59 ET
0.00High0.00Low
0.18Open0.18Pre Close0 Volume533 Open Interest3.00Strike Price0.00Turnover0.00%IV348.52%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.94Leverage Ratio--Theta--Rho--Eff Leverage--Vega
bluebird bio Stock Discussion
Sign in to post a comment
$bluebird bio (BLUE.US)$ way under the money,worth risk small investment potentially great return.,My opinion goes with analyst,under 1.00 crazy price target 3 to 4 dollars,good luck today folks.I bought 1000 see where they are next year.![]()
![]()
![]()
![]()
7
1
$bluebird bio (BLUE.US)$ sad sold early 🫠
2
4
$bluebird bio (BLUE.US)$
till one day we need this kind of service, it may reach the roof 😂
but dont know when will it be
till one day we need this kind of service, it may reach the roof 😂
but dont know when will it be
$bluebird bio (BLUE.US)$ Seems i have majority of posts in this thread since beginning of year! Hehehe! But im going to give one more! IMO from the latest update and from the earnings call! ( Which I recommend you read the earnings call transcript ) I see earnings from this company just getting better and better! IMO im looking for it to just keep growing going forward! And if you read the transcript? Im sure you to will see why i say this. Happy reading![]()
4
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$bluebird bio (BLUE.US)$ Reuters· 1 min ago
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
1
$bluebird bio (BLUE.US)$ Bluebird bio Announces Completion of First Cell Collection for Lyfgenia™ Gene Therapy
$bluebird bio (BLUE.US)$ Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
4
2
$bluebird bio (BLUE.US)$
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
NEWS
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
bluebird bio, Inc. (BLUE) approved inducement grants of 102,700 RSUs to twelve new employees. The RSUs vest equally over four years, in line with NASDAQ rules.
No comment yet
74608670 : Just buy it for a hundred dollars and take a look![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")